Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Nasus Pharma Ltd. is dated March 4, 2026. The report addresses a change in the format of the Company's Special General Meeting of Shareholders scheduled for March 5, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
Due to the security situation in the State of Israel and restrictions on public gatherings, the Company has changed the location of its Special General Meeting of Shareholders to a virtual format only. Shareholders will not be able to attend in person.
Guidance, Outlook, and Risks
The filing highlights a specific operational risk: the security situation in Israel impacting corporate governance activities. No financial guidance, management commentary on future performance, or discussion of contingencies is included in this document.
Key Facts for Investors to Verify
- The Special General Meeting is now virtual-only due to security restrictions.
- The meeting date remains Thursday, March 5, 2026, at 2:00 p.m. Israel time.
- Shareholders must use the provided Zoom link, Meeting ID (948 7426 9962), and Passcode (229406) to attend.
- No financial data is disclosed in this specific filing.